Big Alcohol’s Weed Panic Isn’t Random. The Data Explains It

Big Alcohol’s Weed Panic Isn’t Random. The Data Explains It


Big Alcohol’s Weed Panic Isn’t Random. The Data Explains It

As cannabis beverages gain ground, study after study shows alcohol consumption dropping. You don’t need a conspiracy to explain the panic. You just need the numbers.

Alcohol sales are down. Cannabis beverages are up. And suddenly, a lot of people are very concerned about weed making people puke.

That timing is hard to ignore.

When High Times publisher Josh Kesselman went on TMZ to call out “Big Alcohol” over the latest wave of “scromiting” panic, he didn’t frame it as a medical mystery. He framed it as a business reaction.

“Big alcohol is our biggest foe right now that we know of,” Kesselman said. “And it’s just about money and nothing else.”

New research helps explain why this tension exists at all. Not because it proves who is pushing which narratives, but because it shows why the pressure is real in the first place. For some consumers, cannabis beverages appear to replace alcohol, and drinking drops.

Study: Cannabis beverages are linked to lower alcohol use

Data published in the Journal of Psychoactive Drugs suggests that adults who consume cannabis-infused beverages are more likely to substitute cannabis for alcohol and to reduce how much they drink once they do. The paper is titled “The Exploration of Cannabis Beverage Substitution for Alcohol: A Novel Harm Reduction Strategy.”

The abstract is available on PubMed.

Among the study’s key findings, roughly one-third of respondents reported using cannabis beverages. Those users were more likely to say they substituted cannabis for alcohol than non-users. They also reported fewer weekly alcoholic drinks after starting cannabis beverages and less frequent binge drinking.

NORML summarized the findings in a January 15 post: “Study: Cannabis Beverages Associated With Reduced Alcohol Consumption.”

This isn’t a miracle. It’s a pattern.

None of this means cannabis is for everyone. And it doesn’t mean everyone who drinks is about to switch from beer to a THC seltzer. The study relies on self-reported survey data and cannot prove cause and effect.

What it does add is weight to a pattern researchers keep seeing across different settings. For some adults, legal cannabis functions as a substitute for alcohol. And when that substitution happens, alcohol consumption tends to drop.

Other recent studies point in the same direction

This cannabis beverage study does not exist in isolation. NORML and academic researchers have highlighted several recent papers suggesting cannabis use may be associated with reduced drinking in controlled or clinical contexts.

  • One laboratory study reported that participants consumed less alcohol after using cannabis, including a reported 25 percent reduction in one experimental setup.
  • A clinical trial summary described reductions in alcohol intake following cannabis inhalation compared to placebo.
  • Brown University has also published research summaries connecting cannabis use to lower alcohol consumption under certain conditions.

Taken together, these findings don’t establish a universal rule. But they do support something that’s becoming increasingly obvious in the marketplace. Cannabis is not only competing with alcohol culturally. It may be competing behaviorally, too.

Why this matters for the “Big Alcohol” conversation

To be clear, none of this proves a coordinated fear campaign. We can’t see anyone’s internal strategy documents.

But incentives don’t require conspiracy. If cannabis beverages are associated with lower alcohol consumption for some people, the motivation is obvious. Alcohol has every reason to protect its market, shape the narrative, and slow the momentum of a competing drink category. You don’t need secret meetings to get predictable behavior. You just need money on the line.

Kesselman’s argument reflects that logic. If alcohol companies believe cannabis is winning, he says, the answer is competition, not panic.

“Let’s compete fairly in the market,” he said. “If people like weed better, let them buy the weed, man. Get into the weed game. If you’re so concerned about it, make your own beverages.”

When public conversation is dominated by viral anecdotes and alarming headlines, data matters more than ever. Not to dismiss real medical issues, but to keep the story proportional. If substitution is happening, cannabis beverages are no longer a novelty. They are a pressure point.

The science doesn’t prove who’s behind the loudest narratives. But it makes one thing hard to ignore: the trend is real, and the incentives all point in the same direction.

Related: Big Alcohol Says Weed Will Make You Puke? Hmm…

<p>The post Big Alcohol’s Weed Panic Isn’t Random. The Data Explains It first appeared on High Times.</p>

Source link

Hemp Haze: New Bill Could Limit Cannabinoids to Pharmacies

Hemp Haze: New Bill Could Limit Cannabinoids to Pharmacies

Hemp Haze: New Bill Could Limit Cannabinoids to Pharmacies

A new piece of legislation, Senate Bill 1, aims to significantly restrict how consumers purchase hemp-derived cannabinoids, potentially limiting all sales to pharmacies. Building on previous regulatory changes, this bill seeks to enhance consumer safety and product oversight, but could also impact access and create substantial hurdles for current hemp businesses. The cannabis industry is closely watching as this bill progresses.

Remember When Buying CBD Was Easy? Get Ready for a Potential Shift

For many of us, grabbing a CBD gummy or a hemp-derived tincture has become as routine as picking up groceries. But what if that convenience was about to change dramatically? A fresh piece of legislation, Senate Bill 1, is making waves, and it aims to further tighten the reins on how we access cannabinoids, potentially pushing all sales exclusively into pharmacies. Talk about a plot twist in the evolving story of cannabis regulation!

You might be thinking, “Didn’t we just go through this?” And you’d be right! Lawmakers already approved some significant changes last year, and it looks like this new hemp bill is building on that momentum, striving for even stricter control. If passed, it could reshape the entire landscape of hemp products as we know them, starting as early as 2025.

What’s the Scoop on Senate Bill 1?

So, what exactly does this bill propose? In a nutshell, Senate Bill 1 seeks to centralize the retail of various cannabinoid products derived from hemp. This isn’t just about high-potency THC; it could encompass a broad spectrum of compounds that many currently enjoy for wellness or recreation. The core idea is to shift these sales from your local smoke shop, dispensary, or even online retailers directly into the sterile environment of a pharmacy.

Think about it: no more browsing shelves filled with different brands and formulations at your leisure. Instead, you’d likely be speaking with a pharmacist, similar to how you’d pick up a prescription. While the full details are still emerging, the intent seems clear: more stringent oversight on what’s sold, who sells it, and potentially, who can buy it.

Why the Push for Pharmacy-Only Sales?

It’s fair to ask: why this sudden pivot to pharmacy sales? The overarching theme in many legislative discussions around hemp and cannabis is consumer safety and product regulation. Proponents of such bills often argue that moving hemp products into pharmacies ensures greater quality control, proper labeling, and professional guidance.

Currently, the market for hemp-derived cannabinoids can be a bit of a Wild West, with varying product quality and sometimes questionable claims. Legislators are likely looking to:

  • Enhance Consumer Safety: By ensuring products meet pharmaceutical-grade standards.
  • Prevent Misinformation: Pharmacists could provide accurate usage and dosage information.
  • Address Concerns Over Unregulated Products: Cracking down on products that might contain contaminants or undisclosed ingredients.
  • Strengthen Cannabis Regulation: Creating a more uniform and controlled retail environment for all cannabinoid sales.

While these are valid goals, the method of achieving them is where the debate truly heats up.

The Ripple Effect: Who Gets Impacted?

If Senate Bill 1 becomes law, the impacts would be far-reaching, affecting everyone from consumers to small businesses.

  • For Consumers: Access could become more limited. While pharmacies offer a sense of security, they might not stock the diverse range of products you’re used to. Plus, convenience could take a hit. Will prices increase due to added regulatory hurdles? That’s a strong possibility.
  • For Hemp Businesses: This would be a massive shake-up. Many small and medium-sized hemp businesses rely on direct-to-consumer sales or partnerships with specialized retailers. Forcing products into pharmacies could mean astronomical entry barriers, potentially squeezing out smaller players and consolidating the market into the hands of a few large corporations or pharmaceutical companies. It’s a huge shift from a burgeoning industry to a highly controlled one.

What Happens Next?

This new hemp bill is still in the legislative process, and its journey is far from over. It’s crucial for consumers and stakeholders in the cannabis industry to stay informed and understand the potential implications. These discussions are shaping the future of how we interact with cannabis and hemp, influencing everything from medical access to recreational enjoyment.

Will pharmacies become your one-stop shop for everything from prescriptions to delta-8 gummies? Only time, and the legislative process, will tell. But one thing’s for sure: the conversation around cannabinoid access is only getting louder.

Source link